Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 7/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6214782 | 0.92 | NQO2 (0.59) | NQO2KMT2AMEN1HPGDMAPK1 | |
| SCHEMBL5340606 | 0.90 | NQO2 (0.61) | NQO2KMT2AMEN1HPGDMAPK1 | |
| SCHEMBL5347071 | 0.85 | NQO2 (0.66) | NQO2MTNR1AMTNR1B | |
| SCHEMBL5342615 | 0.82 | NQO2 (0.77) | NQO2HPGDMAPK1MTNR1AMTNR1B | |
| SCHEMBL6219245 | 0.82 | NQO2 (0.63) | NQO2KMT2AMEN1HPGDMAPK1 | |
| SCHEMBL5350520 | 0.78 | MTNR1A (0.76) | NQO2MTNR1AMTNR1B | |
| SCHEMBL5340697 | 0.78 | MTNR1A (0.73) | NQO2MTNR1AMTNR1B | |
| SCHEMBL6217595 | 0.78 | MTNR1A (0.61) | NQO2MAPK1MTNR1AMTNR1B | |
| SCHEMBL5344150 | 0.77 | NQO2 (0.72) | NQO2MTNR1AMTNR1B | |
| SCHEMBL5340996 | 0.77 | NQO2 (1.00) | NQO2HPGDMAPK1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123529-A1 | Substituted biphenyl compounds | LES LABORATOIRES SERVIER (FR) | 2007-05-31 | — | — | US | disclosed |
| US-7161035-B2 | Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2007-01-09 | — | — | US | disclosed |
| US-20040014969-A1 | Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014969-A1 | Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same | MTNR1A, MTNR1B, MC2R | NQO2 406/4885KMT2A 1293/4885MEN1 1674/4885 |
| US-20070123529-A1 | Substituted biphenyl compounds | MTNR1A, MTNR1B, CNR1 | NQO2 522/4885KMT2A 1674/4885MEN1 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.